Sun takes Q4 hit as FDA problems at Halol, generic pricing pressure undermine U.S. sales
admin 26th May 2017 Uncategorised 0Sun Pharma has suffered a gut-wrenching drop in its sales in the U.S. as ongoing regulatory restraints for Sun Pharma’s key API plant in India, along with generic pricing pressures, did a number on the drugmaker’s final quarter.
More: Sun takes Q4 hit as FDA problems at Halol, generic pricing pressure undermine U.S. sales
Source: fierce